Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 733.04 USD -1.2% Market Closed
Market Cap: 77B USD
Section:
 

Relative Value

The Relative Value of one REGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 733.04 USD, Regeneron Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REGN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

5.4
P/S
P/S
Price to Sales
5.4
vs History
58
vs Industry
60
Median 3Y
6.5
Median 5Y
5.8
Industry
8.1
Forward
5.3
More Details
16.9
P/E
P/E
Price to Earnings
16.9
vs History
46
vs Industry
9
Median 3Y
19.2
Median 5Y
15.5
Industry
23.7
Forward
16.7
More Details
15.2
P/OCF
P/OCF
Price to OCF
15.2
vs History
65
vs Industry
11
Median 3Y
17
Median 5Y
16.9
Industry
22.6
More Details
19.9
P/FCFE
P/FCFE
Price to FCFE
19.9
vs History
57
vs Industry
9
Median 3Y
24.8
Median 5Y
21.1
Industry
25.7
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
84
vs Industry
36
Median 3Y
3.5
Median 5Y
3.6
Industry
3.3
More Details
5
EV/S
EV/S
Enterprise Value to Sales
5
vs History
58
vs Industry
59
Median 3Y
6
Median 5Y
5.5
Industry
8.4
Forward
4.9
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
57
vs Industry
60
Median 3Y
6.8
Median 5Y
6.3
Industry
10.4
More Details
16
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16
vs History
25
vs Industry
11
Median 3Y
15.9
Median 5Y
14
Industry
5.9
Forward
14.2
More Details
18.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.2
vs History
20
vs Industry
10
Median 3Y
17.1
Median 5Y
15
Industry
6.4
Forward
14.9
More Details
14.1
EV/OCF
EV/OCF
Enterprise Value to OCF
14.1
vs History
65
vs Industry
13
Median 3Y
15.8
Median 5Y
15.6
Industry
8.2
More Details
18.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.4
vs History
66
vs Industry
9
Median 3Y
22.8
Median 5Y
20.6
Industry
6.4
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
85
vs Industry
26
Median 3Y
3.6
Median 5Y
3.6
Industry
5.8
More Details

Multiples Across Competitors

REGN Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 198 755.5 -162 541.6 -197 377.4 -195 125.1
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 060 -525.7 -572.4 -557.1
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
P/S Multiple
Revenue Growth P/S to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/S: 3 109 172.6
5.4
6%
0.9
FR
Pharnext SCA
OTC:PNEXF
34 198 755.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 060
N/A N/A
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
46%
0.3
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/E: 173.9
16.9
10%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 541.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.7 N/A N/A
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBITDA: 37.4
16
11%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.4 N/A N/A
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBIT: 43.1
18.2
13%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 125.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.